Jmarksto:
The Conference on Retroviruses and Opportunistic Infections (CROI) 2013 runs from March 3 - 6.
Here is a link to the conference program, which includes the specific presentations. I haven't been around for the previous conferences, but this looks pretty comprehensive.
YellowFever:
Sigh, the abstract titles do not look promising...
SB-728-T: Central Memory T Cell Is the Critical Component for Sustained CD4 Reconstitution in HIV Subjects Receiving ZFN CCR5 Modified CD4 T Cells (SB97289T) "Not every patient's CD4 cells went up after our therapy but we think we know why"
"And don't ask us about Viral Load"
Tadeys:
Yellowfever, where did you get this information from?
Did'nt Sangamo say Phase II info was going to be released later this year (meaning not in March, not at CROI)?
Been reading the threads from http://www.investorvillage.com/smbd.asp?mb=1933&mn=50615&pt=msg&mid=12562154 for the past 1/2 hour and can't find any info. Just speculation. Sangamo shares HAVE been going up these past few months...whatever that means( good or bad).
Jmarksto:
Tadeys; Their Feb 14, 2013 Leerink Swann Global Healthcare Conference presentation on their website (you have to register, but they let me in)
http://investor.sangamo.com/events.cfm
Indicates that they will present prelim data the 1st half of 2013 (at CROI) for SB-728-902-5 and SB-728-1101, with complete data by the end of 2013. They also indicate they will be Phase 3 "ready" in 2013.